ES75
TEAS SECTION 71 & 15 RECEIVED
29/05/2026
Voltar para busca
Dado oficial do USPTO
BIONTECH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
01/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 42, 44
Data de depósito
05/04/2019
Data de registro
02/06/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/06/2020
Última transação
01/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
94
Localização do titular
DE
Examinador
HARDY LUDLOW, TARAH KIM
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the stylized wording "BIONTECH".
Titulares e representantes
Titulares
B. S. (pessoa física)
Representantes
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in industry and sciencein particular for use in biotechnologypharmaceuticsmedicine and veterinary medicine
Classe 5
Pharmaceutical and veterinary preparationspreparations for the prevention and treatment of proliferative diseasescancersinfectious diseasesautoimmune diseasesexcept vitamin preparationsmineral food supplementsprobioticsomega 3 preparationsdietetic substances and food supplements for medical and non-medical purposes; vaccinesDNA-based and RNA-based vaccinesadjuvant preparations for use with vaccinesnucleic acids sequencesproteinschemical reagents for medical and veterinary purposesprotein conjugatespeptides featuring antibodies and tumour markers; cell-based immunotherapeutic treatment by way of genetically modified cellsmedicated serums for the treatment of proliferating diseasescancersinfectious diseasesautoimmune diseasesattenuated viruses and particles similar to virusesencapsulated nucleic acids; diagnostic reagents and diagnostic preparations for medical purposes
Classe 42
Scientific research and development in the field of molecular biologybiotechnologypharmaceuticsimmunology and oncologyin particular research and development in the field of medical and veterinary diagnostics and therapy using molecular biologicalgenetic engineering and biotechnological methodsscientific research related to screening for pharmaceutically active compounds; scientific research and development of diagnostic methods and test processes; scientific research and development related to technical planning and conducting of projects in the field of the supplying of medicines; scientific consultancy services in the field of research and development of therapies and medical preparations; providing of scientific expertise in the nature of scientific study and research in the field of medicine; scientific research and development for medical and veterinary purposes; conducting and evaluating medical and pharmaceutical studiestestinganalysis and evaluation of goods/services of others to determine conformity with certification standards
Classe 44
Medical services; providing medical care services and consultation related thereto; urgent medical care centers; pharmaceutical and medical consultancy; providing healthcare information and advisory services in the healthcare field; medical consultation services featuring preparation of reports relating to medical and pharmaceutical services; medical and pharmaceutical consultation; all the aforesaid services other than in the field of bione therapy or other types of therapy combined with bione therapy
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/05/2026
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/03/2026
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
02/06/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
24/02/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
24/02/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
24/02/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
24/02/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
24/02/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
24/02/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
15/04/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
18/10/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
28/09/2020
FIMP
FINAL DISPOSITION PROCESSED
28/09/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/09/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
02/06/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/03/2020
PUBO
PUBLISHED FOR OPPOSITION
17/03/2020
GPNX
NOTIFICATION PROCESSED BY IB
13/03/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/02/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
26/02/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/02/2020
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
13/02/2020
ALIE
ASSIGNED TO LIE
11/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/02/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/02/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/02/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/02/2020
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
24/10/2019
RFNT
REFUSAL PROCESSED BY IB
30/08/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
15/08/2019
RFRR
REFUSAL PROCESSED BY MPU
15/08/2019
MAFR
APPLICATION FILING RECEIPT MAILED
26/07/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
23/07/2019
CNRT
NON-FINAL ACTION WRITTEN
22/07/2019
DOCK
ASSIGNED TO EXAMINER
22/07/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/07/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/07/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BIONTECH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.